Canada - English - Health Canada

novo nordisk canada inc - coagulation factor ix (recombinant), pegylated - powder for solution - 2000unit - coagulation factor ix (recombinant), pegylated 2000unit - hemostatics

Canada - English - Health Canada

csl behring canada inc - coagulation factor ix (recombinant), albumin fusion protein (rix-fp) - kit - 3500unit - coagulation factor ix (recombinant), albumin fusion protein (rix-fp) 3500unit - hemostatics

Israel - English - Ministry of Health

sanofi - aventis israel ltd - coagulation factor viii - powder and solvent for solution for injection - coagulation factor viii 1500 iu - coagulation factor viii - eloctate [antihemophilic factor (recombinant fc fusion protein)] is a long-acting antihemophilic factor (recombinant) indicated in adults and children12 years of age and older with hemophilia a (congenital factor viii deficiency) for:• control and prevention of bleeding episodes.• routine prophylaxis to prevent or reduce the frequency of bleeding episodes.• perioperative management (surgical prophylaxis).eloctate is not indicated for the treatment of von willebrand disease.

Israel - English - Ministry of Health

sanofi - aventis israel ltd - coagulation factor viii - powder and solvent for solution for injection - coagulation factor viii 2000 iu - coagulation factor viii - eloctate [antihemophilic factor (recombinant fc fusion protein)] is a long-acting antihemophilic factor (recombinant) indicated in adults and children12 years of age and older with hemophilia a (congenital factor viii deficiency) for:• control and prevention of bleeding episodes.• routine prophylaxis to prevent or reduce the frequency of bleeding episodes.• perioperative management (surgical prophylaxis).eloctate is not indicated for the treatment of von willebrand disease.

Israel - English - Ministry of Health

sanofi - aventis israel ltd - coagulation factor viii - powder and solvent for solution for injection - coagulation factor viii 3000 iu - coagulation factor viii - eloctate [antihemophilic factor (recombinant fc fusion protein)] is a long-acting antihemophilic factor (recombinant) indicated in adults and children12 years of age and older with hemophilia a (congenital factor viii deficiency) for:• control and prevention of bleeding episodes.• routine prophylaxis to prevent or reduce the frequency of bleeding episodes.• perioperative management (surgical prophylaxis).eloctate is not indicated for the treatment of von willebrand disease.

Israel - English - Ministry of Health

sanofi - aventis israel ltd - coagulation factor viii - powder and solvent for solution for injection - coagulation factor viii 750 iu - coagulation factor viii - eloctate [antihemophilic factor (recombinant fc fusion protein)] is a long-acting antihemophilic factor (recombinant) indicated in adults and children12 years of age and older with hemophilia a (congenital factor viii deficiency) for:• control and prevention of bleeding episodes.• routine prophylaxis to prevent or reduce the frequency of bleeding episodes.• perioperative management (surgical prophylaxis).eloctate is not indicated for the treatment of von willebrand disease.

Canada - English - Health Canada

novo nordisk canada inc - coagulation factor ix (recombinant), pegylated - powder for solution - 3000unit - coagulation factor ix (recombinant), pegylated 3000unit

Malta - English - Medicines Authority

baxter healthcare limited - factor viii inhibitor bypassing fraction 500 u - powder and solvent for solution for injection

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

takeda malaysia sdn bhd - factor viii bypassing fraction -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

takeda malaysia sdn bhd - factor viii bypassing fraction -